TransMedics Group, Inc. (NASDAQ: TMDX) saw its stock price surge 9.33% in after-hours trading on Thursday, following the release of its exceptional first-quarter 2025 financial results that significantly outperformed analyst expectations.

The medical technology company reported quarterly earnings of $0.70 per share, surpassing the analyst consensus estimate of $0.25 by an impressive 180%. This represents a 100% increase from the $0.35 per share reported in the same period last year. TransMedics' quarterly sales reached $143.54 million, beating the analyst consensus estimate of $123.66 million by 16.07% and marking a 48.21% increase from the $96.85 million reported in the previous year.

Other highlights from the Q1 report include income from operations of $27.443 million, far exceeding the IBES estimate of $10.1 million. The company also achieved a robust gross margin of 61% and reported a net income of $25.682 million. Looking ahead, TransMedics provided a strong full-year revenue outlook of $565-585 million, further bolstering investor confidence. The company's outstanding performance across multiple financial metrics likely contributed to the significant after-hours stock price increase.